Toward “CO in a Pill”: Silica-Immobilized Organic CO Prodrugs for Studying the Feasibility of Systemic Delivery of CO via In Situ Gastrointestinal CO Release
Molecular Pharmaceutics · 2023
DOI: 10.1021/acs.molpharmaceut.2c01104 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2023. Verfasst von Xiaoxiao Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, Georgia 30303, United States. Hauptthemen laut MEDLINE: Prodrugs. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
Carbon monoxide (CO), an endogenous signaling molecule, is known to exert a range of pharmacological effects, including anti-inflammation, organ protection, and antimetastasis in various animal models. We have previously shown the ability of organic prodrugs to deliver CO systemically through oral administration. As part of our efforts for the further development of these prodrugs, we are interested in minimizing the potential negative impact of the "carrier" portion of the prodrug. Along this line, we have previously published our work on using benign "carriers" and physically trapping the "carrier" portion in the gastrointestinal (GI) tract. We herein report our feasibility studies on using immobilized organic CO prodrugs for oral CO delivery while minimizing systemic exposure to the prodrug and the "carrier portion." In doing so, we immobilize a CO prodrug to silica microparticles, which are generally recognized as safe by the US FDA and known to provide large surface areas for loading and water accessibility. The latter point is essential for the hydrophobicity-driven activation of the CO prodrug. Amidation-based conjugation with silica is shown to provide 0.2 mmol/g loading degree, effective prodrug activation in buffer with comparable kinetics as the parent prodrug, and stable tethering to prevent detachment. One representative silica conjugate, SICO-101, is shown to exhibit anti-inflammation activity in LPS-challenged RAW264.7 cells and to deliver CO systemically in mice through oral administration and GI CO release. We envision this strategy as a general approach for oral CO delivery to treat systemic and GI-specific inflammatory conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry and Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, Georgia 30303, United States.
- Department of Pharmaceutics and Drug Delivery, University of Mississippi School of Pharmacy, University, Mississippi 38677, United States.
- Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, Tennessee 38613, United States.
ORCID-Profile: Xiaoxiao Yang, Binghe Wang
Förderung
- NIDDK NIH HHS
- NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
- Georgia Research Alliance
- National Institutes of Health
Zitieren
APA
Yang, X., Tripathi, R., Wang, M., Lu, W., Anifowose, A., Tan, C., & Wang, B. (2023). Toward “CO in a Pill”: Silica-Immobilized Organic CO Prodrugs for Studying the Feasibility of Systemic Delivery of CO via In Situ Gastrointestinal CO Release. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.2c01104
Vancouver
Yang X, Tripathi R, Wang M, Lu W, Anifowose A, Tan C, et al. Toward “CO in a Pill”: Silica-Immobilized Organic CO Prodrugs for Studying the Feasibility of Systemic Delivery of CO via In Situ Gastrointestinal CO Release. Molecular Pharmaceutics. 2023. doi:10.1021/acs.molpharmaceut.2c01104
BibTeX
@article{Yang2023,
author = {Yang, Xiaoxiao and Tripathi, Ravi and Wang, Minjia and Lu, Wen and Anifowose, Abiodun and Tan, Chalet and Wang, Binghe},
title = {Toward “CO in a Pill”: Silica-Immobilized Organic CO Prodrugs for Studying the Feasibility of Systemic Delivery of CO via In Situ Gastrointestinal CO Release},
journal = {Molecular Pharmaceutics},
year = {2023},
doi = {10.1021/acs.molpharmaceut.2c01104}
}
EUVIMED